Celldex Therapeutics CLDX Business Segments — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's business segments — other research and development expense?
- Celldex Therapeutics (CLDX) reported business segments — other research and development expense of $4.88M in Q1 2026.
- How has Celldex Therapeutics's business segments — other research and development expense changed year-over-year?
- Celldex Therapeutics's business segments — other research and development expense increased by 48.9% year-over-year, from $3.27M to $4.88M.
- What is the long-term trend for Celldex Therapeutics's business segments — other research and development expense?
- Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — other research and development expense has grown at a 34.5% compound annual growth rate (CAGR), from $6.35M to $15.48M.
- What does business segments — other research and development expense mean?
- This metric captures miscellaneous research and development costs within the primary business segment that do not fall into major categories like personnel or direct product development. It may include consulting fees, regulatory filing costs, or specialized outsourced research services. Monitoring this helps identify secondary drivers of the company's overall research expenditure.